Two-drug antiretroviral therapy with doravirine/dolutegravir - a prospective cohort study
Recruiting
- Conditions
- B24Unspecified human immunodeficiency virus [HIV] disease
- Registration Number
- DRKS00030471
- Lead Sponsor
- Med. Klinik und Poliklinik IV, Sektion Klinische Infektiologie, LMU Klinikum Innenstadt, Ludwig-Maximilians-Universität München
- Brief Summary
DOR and DTG (DoDo) can be a valuable 2DR option also in heavily pretreated people living with HIV. DoDo proved to be both well tolerated and durably potent during about 2639 patient-months of follow-up. More data on this 2-drug-regimen are clearly needed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
• Persons being cared for in clinics and private practices in German-speaking areas
• Age >18 years
• documented HIV-1-infection
• documented previous treatment with antiretroviral therapy (ART)
• switch of ART to exclusively DOR/DTG
• written informed consent after discussion of patient information
Exclusion Criteria
• Inability to consent
• switch of ART to DOR/DTG in a clinic/practice not participating in the study
• antiretroviral therapy including other substances except DOR/DTG
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) Description of the clinical situation resulting in the prescriptrion of DOR/DTG as a 2-DR. <br>2) Documentation of the clinicaL and virological efficacy of the 2-DR DOR/DTG
- Secondary Outcome Measures
Name Time Method 1) Frequency and causes for off-label prescription of the 2-DR DOR/DTG. <br><br>2) Durability of the 2-DR DOR/DTG:<br>*Time to switch to another combination<br>*Reason for switching to another combination